INVEGA SUSTENNA Drug Patent Profile

When do Invega Sustenna patents expire, and what generic alternatives are available?

Invega Sustenna is a drug marketed by Janssen Pharms and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has thirty-eight patent family members in twenty-nine countries.

The generic ingredient in INVEGA SUSTENNA is paliperidone palmitate. There are thirty-eight drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the paliperidone palmitate profile page.

DrugPatentWatch^® Generic Entry Outlook for Invega Sustenna

Invega Sustenna was eligible for patent challenges on December 19, 2010.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be January 26, 2031. This may change due to patent challenges or generic licensing.

There have been fourteen patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

There are five tentative approvals for the generic drug (paliperidone palmitate), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

Summary for INVEGA SUSTENNA

International Patents:	38
US Patents:	1
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for INVEGA SUSTENNA

Paragraph IV (Patent) Challenges for INVEGA SUSTENNA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
INVEGA SUSTENNA	Extended-release Injectable Suspension	paliperidone palmitate	39 mg/0.25 mL, 78 mg/0.5 mL, 117 mg/0.75 mL, 156 mg/mL and 234 mg/1.5 mL	022264	1	2017-11-21

US Patents and Regulatory Information for INVEGA SUSTENNA

INVEGA SUSTENNA is protected by two US patents.

This potential generic entry date is based on patent 5,254,556.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Janssen Pharms	INVEGA SUSTENNA	paliperidone palmitate	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	022264-001	Jul 31, 2009		RX	Yes	Yes	9,439,906
Janssen Pharms	INVEGA SUSTENNA	paliperidone palmitate	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	022264-004	Jul 31, 2009		RX	Yes	Yes	9,439,906
Janssen Pharms	INVEGA SUSTENNA	paliperidone palmitate	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	022264-002	Jul 31, 2009		RX	Yes	Yes	9,439,906

International Patents for INVEGA SUSTENNA

When does loss-of-exclusivity occur for INVEGA SUSTENNA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

Colombia

Croatia

Cyprus

Denmark

Ecuador

Eurasian Patent Organization

European Patent Office

Finland

Guatemala

Hong Kong

Hungary

Israel

Japan

Lithuania

Malaysia

New Zealand

Nicaragua

Poland

Portugal

Serbia

Slovenia

South Korea

Spain

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering INVEGA SUSTENNA around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	122349
Australia	4443689
Australia	614437

Supplementary Protection Certificates for INVEGA SUSTENNA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0904081	CA 2011 00020	Denmark
0904081	416	Finland
0904081	C00904081/01	Switzerland		PRODUCT NAME: PALIPERIDON PALMITATESTER; REGISTRATION NO/DATE: SWISSMEDIC 60466 20101215

INVEGA SUSTENNA Investment Scenario and Patent-Focused Fundamentals Analysis (Exclusivity, Litigation Risk, and Generic/Biosimilar Outlook)

Last updated: July 28, 2026

INVEGA SUSTENNA (paliperidone palmitate) is a long-acting injectable antipsychotic with a patent estate anchored to its composition, manufacturing, and delivery systems, plus U.S. regulatory exclusivities tied to the innovator product. From an investment lens, the key drivers are (1) U.S. and ex-U.S. patent expiry cadence for the key Orange Book-listed claims, (2) the probability-weighted timeline for generic entry (505(b)(2)/ANDA) and any potential patent carve-outs via Paragraph IV, (3) settlement dynamics that affect “at-risk” launch timing, and (4) dose-mix and persistence in schizophrenia and schizoaffective disorder markets.

Because INVEGA SUSTENNA is listed in the U.S. as an NDA product and not a biologic, the primary competitive threat is generic paliperidone palmitate LAI entry, not a biosimilar. The competitive framework is dominated by the long-acting depot manufacturing supply chain, device/needle administration constraints, and the claim scope around particle engineering, esterification/hydrolysis control, and release kinetics.

---

What patents protect INVEGA SUSTENNA (paliperidone palmitate) in the U.S., and how broad is the estate?

Direct answer: The U.S. patent estate for INVEGA SUSTENNA is protection against generic manufacture and marketing through Orange Book-listed patents covering the active ingredient’s formulation/combination and manufacturing-related claim elements, plus secondary patents that target specific dosage forms, particle properties, and process steps. Risk to generic entry concentrates on patents that remain unexpired for the exact strengths (notably 39 mg, 78 mg, 117 mg, 156 mg) and that are asserted during infringement actions.

Which patent types matter most for generic paliperidone palmitate LAI entry?

In long-acting injectables, the highest leverage patents typically fall into three buckets:

1. Formulation and composition of matter

   • Claim coverage around the composition of paliperidone palmitate in the depot matrix.
   • Particle size distribution, crystallinity/polymorph-related descriptors, surfactant/vehicle selections, and stabilizers that influence injectability and release.

2. Manufacturing and process patents

   • Steps controlling esterification conversion quality, residual solvent/impurity profile, milling or dispersion parameters, and hold times that affect particle attributes and release.

3. Use or method-of-use claims (where present)

   • Clinical regimen claims can add barriers if a generic attempts a label carve-out, though enforcement depends on claim language and whether the generic’s proposed labeling triggers induced infringement.

How many INVEGA SUSTENNA patents are on file, and where does the “core” protection sit?

For an investment model, the count alone is less predictive than:

• how many patents are expiring in the near window,
• how many are listed against the exact NDA strengths, and
• how many are actively litigated or have prior Paragraph IV history.

A patent portfolio that is “deep” but where the remaining claims expire in a single tight window offers less incremental protection than one with staggered expiration across formulation and process layers.

---

When does INVEGA SUSTENNA lose exclusivity in the U.S., and what is the practical launch timeline for generics?

Direct answer: Exclusivity and patent expiry govern the earliest legally permissible date for generic launch. Practically, “generic date” is the later of (a) patent expiration for the asserted/essential Orange Book claims and (b) any post-expiry injunction carve-outs or settlement-based “no-launch until” terms.

How to model exclusivity vs. patent expiry

For NDA injectables like INVEGA SUSTENNA, the investment timeline should separate:

• Regulatory exclusivity (e.g., new chemical entity or data exclusivity, if applicable to the initial approval context), from
• Patent exclusivity (Orange Book patents that block marketing).

Even when a regulatory exclusivity clock ends, patent expiration can still delay competition.

What launch timing inputs move the valuation

The valuation-sensitive inputs are:

• probability and timing of successful Paragraph IV challenges,
• likelihood of “carve-out” settlements (delayed entry in exchange for dismissal),
• court decisions that invalidate or narrow key claims,
• injunction enforceability and duration.

---

Which companies are challenging INVEGA SUSTENNA through Paragraph IV, and what does litigation history imply for entry risk?

Direct answer: Paragraph IV challenges are the usual mechanism for at-risk entry in U.S. generic markets. Litigation outcomes determine whether generics enter at the first legal date or later.

What to watch in any INVEGA SUSTENNA Paragraph IV docket

For each filer and each asserted patent:

• whether the challenge is to all strengths or only selected doses,
• whether the court’s ruling is invalidity vs. non-infringement,
• whether appeals delay final entry dates,
• whether a settlement agreement bars entry until a defined date.

Investment interpretation of litigation posture

• A history of multiple unsuccessful Paragraph IV challenges against depot injectables is typically consistent with robust formulation/process claim coverage.
• Conversely, a pattern of settlements that include short “shared markets” indicates that at least one layer of patent coverage is weaker, often manufacturing-oriented rather than composition-oriented.

---

What is the Orange Book status of INVEGA SUSTENNA, and how does listing affect generic launch dates?

Direct answer: Orange Book listings are the practical barrier list for generic applicants. If a generic files an ANDA referencing the NDA and includes patents listed for the specific dosage forms/strengths, then Paragraph IV triggers a stay regime that can delay FDA approval and marketing.

How Orange Book listings are mapped to competitive risk

For each INVEGA SUSTENNA strength:

• identify the patents “listed for that strength,”
• compare the earliest patent expiration and associated exclusivity,
• identify whether patents are device or process oriented versus pure composition.

For investors, the key is whether the “earliest-to-expire” patents are easy to design around. Process-layer patents that can be engineered around with a different manufacturing route can reduce blocking effect, while composition-level claims tend to be harder to circumvent.

---

What formulations are protected for INVEGA SUSTENNA, and how do they constrain generic substitutes?

Direct answer: Depot injectables are typically protected by claim language describing particle properties and the depot matrix that controls release over the dosing interval. Generic versions must match the release profile and critical quality attributes to avoid infringement and to clear FDA quality/bioequivalence expectations.

Dose-specific constraints

INVEGA SUSTENNA’s dosing involves initiation and maintenance schedules. The investment question is whether generic challenges target:

• initial dose strengths (39 mg/78 mg),
• maintenance strengths (117 mg/156 mg), or both.

If only one tier is challenged first, the competitive ramp can be slower.

Manufacturing similarity requirements

Even if a generic can clear clinical/PK equivalence requirements, infringement can turn on:

• particle size distribution targets,
• residual impurities and solvents,
• sterilization and filtration parameters,
• mixing/holding conditions that affect crystallinity.

---

Does INVEGA SUSTENNA have method-of-use patent exposure, and what label carve-outs matter?

Direct answer: Method-of-use exposure is a secondary risk driver for long-acting depot products. If asserted claims tie directly to dosing regimens in the U.S. label, a generic must either challenge those claims or maintain a label that avoids triggering infringement.

Investment relevance

• If method-of-use patents are present and enforceable, they can delay market penetration even after composition/process patents expire.
• If the label can be carved out without commercial harm, generics can launch earlier with lower litigation probability.

---

How strong is the patent estate for INVEGA SUSTENNA versus competing long-acting paliperidone products (e.g., INVEGA TRINZA and other LAIs)?

Direct answer: INVEGA TRINZA (paliperidone palmitate 3-month) is a separate depot product with its own formulation and release-duration profile. Competitive overlap exists at the “patient convenience” layer, but patent risk is product-specific.

What a comparative estate analysis should measure

For each paliperidone LAI:

• earliest expiration of core formulation/process patents,
• presence/absence of multiple staggered patents versus a single expiry cluster,
• litigation/settlement history,
• whether competitors have designed around without quality/pK compromise.

From an investment standpoint, the stronger estate is the one with:

• later earliest expiry,
• higher claim count in the near window,
• litigation outcomes favorable to the innovator,
• fewer “design-around” pathways.

---

What FDA regulatory status and pathway issues affect INVEGA SUSTENNA competition?

Direct answer: Generics compete via ANDA or 505(b)(2) referencing established data. For depot formulations, chemistry, manufacturing, and controls (CMC) and product performance specs are central to regulatory acceptance, which can slow launch even after legal exclusivity ends.

Regulatory features investors track

• whether applicants pursue an “at-risk” launch after ANDA approval,
• CMC comparability challenges (particle size, release profile, impurities),
• post-approval changes that can trigger FDA correspondence or quality actions.

---

What generic entry risks exist for INVEGA SUSTENNA across U.S. strengths and how could entry impact revenue?

Direct answer: Generic entry risk is dose- and claim-dependent. Revenue impact typically concentrates in the highest-volume strengths and in patients stable on a specific maintenance dose. Patent carve-outs can allow partial entry while limiting substitution.

How to structure a revenue-at-risk model

Model three substitution curves:

1. Speed to first lawful launch (legal + settlement driven).
2. Rate of uptake (pharmacy switching and prescriber inertia).
3. Line-of-therapy effects (whether patients remain on paliperidone LAI vs. shift within LAI class).

Key additional drivers:

• payer formulary placement and prior authorization rules,
• patient adherence and “missed dose” consequences,
• competitive positioning vs. alternative LAIs (rilpivine-based, aripiprazole LAIs, olanzapine pamoate, and others).

---

What manufacturing/IP barriers block generic paliperidone palmitate LAI launches?

Direct answer: For depot injectables, the biggest barriers are manufacturing reproducibility and CMC alignment with the innovator’s critical quality attributes that underpin performance and, in many cases, infringement analyses.

Common barrier categories

• Control of dispersion and particle engineering.
• Batch-to-batch consistency for release kinetics.
• Scale-up robustness and validated sterilization/packaging processes.
• Sterile suspension handling, needle compatibility, and device-level constraints.

These factors can translate into delayed “ready-to-market” timelines even after a legal win.

---

What settlement agreements and injunction dynamics would delay INVEGA SUSTENNA generic entry?

Direct answer: Settlements often allocate “design-around” and “market-entry” dates. Injunctions can freeze launch until final resolution, particularly when asserted patents are composition/process patents with strong likelihood of being found infringed.

Investment implication

• A settlement that sets a later entry date is a direct delay input.
• A dismissal without a no-launch clause increases at-risk launch probability.
• Appeals can extend timelines without resolving the economic value to either party.

---

Key Takeaways

• INVEGA SUSTENNA competition risk is primarily generic (ANDA/505(b)(2)) driven, not biosimilar driven.
• The valuation hinge is the Orange Book-linked patent expiry cadence by strength and the history of Paragraph IV litigation outcomes and settlement terms.
• Depot injectable barriers shift the “effective” competition start date: even when legal entry is possible, manufacturing and CMC readiness can delay commercialization.
• Revenue-at-risk modeling should be dose-specific and reflect substitution curves, formulary dynamics, and potential partial entry via carve-outs.

---

FAQs

1. What is the main U.S. exclusivity blocker for generic versions of INVEGA SUSTENNA: Orange Book patents or regulatory exclusivity?
2. Do generic ANDA filings for paliperidone palmitate depot typically challenge all strengths or only selected doses first?
3. How do formulation and manufacturing process patents affect whether a generic can design around INVEGA SUSTENNA?
4. What litigation outcome patterns most often predict delayed market entry for long-acting injectable generics?
5. How should investors translate patent expiry timing into an FDA approval-to-launch schedule for INVEGA SUSTENNA substitutes?

---

References

1. U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed via FDA Orange Book).
2. FDA. Generic Drug User Fee Amendments and ANDA approval framework. (FDA guidance and regulatory framework).
3. FDA. ANDA Chemistry, Manufacturing, and Controls expectations for generic drug products. (FDA guidance).